Prognostic significance of p53 codon 72 polymorphism in lung carcinomas

European Journal of Cancer

Volumn 35, Issue 2, 1999, Pages 226-230

  Wang, Y C ^a   Lee, H S ^a   Chen, S K ^a   Chang, Y Y ^a   Chen, C Y ^b  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Lung cancer; p53 tumour suppressor gene; Polymorphism; Prognosis

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GENETICS; CANCER SURVIVAL; CODON; DNA POLYMORPHISM; FEMALE; GENOTYPE; HUMAN; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE;

AGED; CODON; FEMALE; FOLLOW-UP STUDIES; GENES, P53; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, GENETIC; PROGNOSIS; SMOKING; SURVIVAL ANALYSIS; TAIWAN;

EID: 0033083217     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00369-4     Document Type: Article

References (26)

1. Department of Health, The Executive Yuan. Republic of China. General health statistics. In Health and Vital Statistics, Republic of China. Taipei, R. O. C. Press, 1998, 86-108.
2. Okada T., Kawashima K., Fukushi S., Minakuchi T., Nishimura S. Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer. Cancer Res. 4:1994;333-340.
3. Goto I., Yoneda S., Yamamoto M., Kawajiri K. Prognostic significance of germ line polymorphisms of the CYP1A1 and glutathione S-transferase genes in patients with non-small cell lung cancer. Cancer Res. 56:1996;3725-3730.
4. Kawashima K., Nomura S., Hirai H., et al. Correlation of L-myc RFLP with metastasis, prognosis and multiple cancer in lung-cancer patients. Int J Cancer. 50:1992;557-561.
5. Weston A., Perrin L.S., Forrester K., et al. Allelic frequency of a p53 polymorphism in human lung cancer. Cancer Epidemiol, Biomarkers Prev. 1:1992;481-483.
6. Kawajiri K., Nakachi K., Imai K., Watanabe J., Hayashi S.I. Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis. 14:1993;1085-1089.
7. Murata M., Tagawa M., Kimura M., Kimura H., Watanabe S., Saisho H. Analysis of a germ line polymorphism of the p53 gene in lung cancer patients; discrete results with smoking history. Carcinogenesis. 17:1996;261-264.
8. Jin X., Wu X., Roth J.A., et al. Higher lung cancer risk for younger African-Americans with the Pro/Pro p53 genotype. Carcinogenesis. 16:1995;2205-2208.
9. Matlashewski G.J., Tuck S., Pim D., Lamb P., Schneider J., Crawford L.V. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol. 7:1987;961-963.
10. Murata M., Tagawa M., Kimura H., Kakisawa K., Shirasawa H., Fujisawa T. Correlation of the mutation of p53 gene and the polymorphism at codon 72 in smoking-related non-small cell lung cancer patients. Int J Oncol. 12:1998;577-581.
11. Lehman T.A., Bennett W.P., Metcalf R.A., et al. p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res. 51:1991;4090-4096.
12. Lee ET. Statistical Methods for Survival Data Analysis, 2nd edn. New York, John Wiley, 1992, 1-7.
13. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 53:1958;457-481.
14. The Lifetest Procedure. In SAS Technical Report: P-179. Additional SAS/STAT Procedures, Release 6.03. Cary, NC, SAS Institute, 1988, 49-90.
15. Greenblatt M.S., Bennett W.P., Hollstein M., Harris C.C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:1994;4855-4878.
16. Zhang W., Hu G., Deisseroth A. Polymorphism at codon 72 of the p53 gene in human acute myelogenous leukemia. Gene. 117:1992;271-275.
17. Ribeiro J.C., Barnetson A.R., Fisher R.J., Mameghan H., Russell P.J. Relationship between radiation response and p53 status in human bladder cancer cells. Int J Radiat Biol. 72:1997;11-20.
18. Wang Y.C., Chen C.Y., Chen S.K., Cherng S.H., Ho W.L., Lee H. High frequency of deletion mutations in p53 gene from squamous-cell lung cancer patients in Taiwan. Cancer Res. 58:1998;328-333.
19. Harris C.C. Structure and function of the p53 tumor suppressor gene: clue for rational cancer therapeutic strategies. JNCI. 88:1996;1442-1455.
20. Gottlieb T.M., Oren M. p53 in growth control and neoplasia. Biochem Biophys Acta. 1287:1996;77-102.
21. Birgander R., Själander A., Rannug A., et al. p53 polymorphisms and haplotypes in lung cancer. Carcinogenesis. 16:1995;2233-2236.
22. Själander A., Birgander R., Kivelä A., Beckman G. p53 polymorphisms and haplotypes in different ethnic groups. Hum Hered. 45:1995;144-149.
23. Pleasants L.M., Hansen M.F. Identification of a polymorphism in intron 2 of the p53 gene. Hum Genet. 93:1994;607-608.
24. Buller R.E., Sood A., Fullenkamp C., Sorosky J., Powills K., Anderson B. The influence of the p53 codon 72 polymorphism on ovarian carcinogenesis and prognosis. Cancer Gene Ther. 4:1997;239-245.
25. Ge H., Lam W.K., Lee J., et al. Detection and evaluation of p53 intron 2 polymorphism in lung carcinomas in Hong Kong. Int J Cancer. 69:1996;120-124.
26. Tagawa M., Murata M., Kimura H. Prognostic value of mutations and a germ line polymorphism of the p53 gene in non-small cell lung carcinoma: association with clinicopathological features. Cancer Lett. 128:1998;93-99.